Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspectiveBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32018-12-039OAAI
The European Medicines Agency's approval of new medicines for type 2 diabetesDIABETES OBESITY & METABOLISMIF5.72018-05-3020OAAI
Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetesmellitus: risk assessment vs. risk aversion by Zannad et al.EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPYIF6.12017-04-242OAAI
The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitorsEUROPEAN HEART JOURNALIF35.62016-02-071OAAI
The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitorsEUROPEAN HEART JOURNALIF35.62015-12-260OAAI
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA AssessmentNEW ENGLAND JOURNAL OF MEDICINEIF78.52014-02-27395PREAI
Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factorHUMAN MOLECULAR GENETICSIF3.22006-12-21111PREAI
Characterization of the human and mouse genes encoding the tuberoinfundibular peptide of 39 residues, a ligand of the parathyroid hormone receptor familyJOURNAL OF ENDOCRINOLOGYIF3.92002-07-0116OAAI
A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannomaBONEIF3.62001-10-0140PREAI
Changing serine-485 to alanine in the opossun parathyroid hormone (PTH)/PTH-related peptide receptor enhances PTH stimulation of phospholipase C in a stably transfected human kidney cell line:: A useful model for PTH-analog screening?BONEIF3.62001-02-013PREAI
Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat modelBONEIF3.61996-04-0114PREAI